Additional Relevant Details
Advancing Treatment Approaches to Optimize Patient-Centered Care
During WFH 2016, Shire researchers will address the PROPEL study, which compares the safety and efficacy of ADYNOVATE [Antihemophilic Factor [Recombinant], PEGylated] following pharmacokinetic (PK)-guided prophylaxis targeting two different Factor VIII trough levels. The novel design of the study is built upon preliminary data indicating that maintaining higher trough levels may be able to help enhance bleed protection and help more patients reach zero bleeds.In addition, the company has initiated research on an innovative patient-reported outcome (PRO) measure: Goal Attainment Scaling – Hematology (GOAL-Hēm). The measure is intended to support broader bleeding disorder management by supplementing standard clinical outcome measures with those that are patient-centered, customizable and sensitive to change across patients and patient populations.